Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)

S. A. Burgers; C. de Gooijer; R. Cornelissen; J. G. Aerts; B. Biesma; R. V. Heemst; M. Youssef-El Soud; H. J. M. Groen; A. J. Staal-van den Brekel; G. Bootsma; J. H. E. M. Schijen; P. Baas; E. Giovannetti; J. F. de Vries; F. A. Hogenboom; D. C. M. de Wit; M. C. W. Mahn-Schaefers; F. Lalezari; V. van de Noort; J. Stigt

Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)

S. A. Burgers, C. de Gooijer, R. Cornelissen, J. G. Aerts, B. Biesma, R. V. Heemst, M. Youssef-El Soud, H. J. M. Groen, A. J. Staal-van den Brekel, G. Bootsma, J. H. E. M. Schijen, P. Baas, E. Giovannetti, J. F. de Vries, F. A. Hogenboom, D. C. M. de Wit, M. C. W. Mahn-Schaefers, F. Lalezari, V. van de Noort, J. Stigt

Onderzoeksoutput › Academic

Originele taal-2	English
Aantal pagina's	2
Tijdschrift	Annals of Oncology
Volume	30
Status	Published - okt.-2019
Evenement	44th Congress of the European-Society-for-Medical-Oncology (ESMO) - Barcelona, Spain Duur: 27-sep.-2019 → 1-okt.-2019

Handle.net

Permanente koppeling

Citeer dit

Burgers, S. A., de Gooijer, C., Cornelissen, R., Aerts, J. G., Biesma, B., Heemst, R. V., Youssef-El Soud, M., Groen, H. J. M., Staal-van den Brekel, A. J., Bootsma, G., Schijen, J. H. E. M., Baas, P., Giovannetti, E., de Vries, J. F., Hogenboom, F. A., de Wit, D. C. M., Mahn-Schaefers, M. C. W., Lalezari, F., van de Noort, V., & Stigt, J. (2019). Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19). Annals of Oncology, 30.

@article{33f14edbb8a1431eb13190b5ffd65373,

title = "Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)",

author = "Burgers, {S. A.} and {de Gooijer}, C. and R. Cornelissen and Aerts, {J. G.} and B. Biesma and Heemst, {R. V.} and {Youssef-El Soud}, M. and Groen, {H. J. M.} and {Staal-van den Brekel}, {A. J.} and G. Bootsma and Schijen, {J. H. E. M.} and P. Baas and E. Giovannetti and {de Vries}, {J. F.} and Hogenboom, {F. A.} and {de Wit}, {D. C. M.} and Mahn-Schaefers, {M. C. W.} and F. Lalezari and {van de Noort}, V. and J. Stigt",

year = "2019",

month = oct,

language = "English",

volume = "30",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "44th Congress of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 27-09-2019 Through 01-10-2019",

}

Burgers, SA, de Gooijer, C, Cornelissen, R, Aerts, JG, Biesma, B, Heemst, RV, Youssef-El Soud, M, Groen, HJM, Staal-van den Brekel, AJ, Bootsma, G, Schijen, JHEM, Baas, P, Giovannetti, E, de Vries, JF, Hogenboom, FA, de Wit, DCM, Mahn-Schaefers, MCW, Lalezari, F, van de Noort, V & Stigt, J 2019, 'Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)', Annals of Oncology, vol. 30.

TY - JOUR

T1 - Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma

T2 - 44th Congress of the European-Society-for-Medical-Oncology (ESMO)

AU - Burgers, S. A.

AU - de Gooijer, C.

AU - Cornelissen, R.

AU - Aerts, J. G.

AU - Biesma, B.

AU - Heemst, R. V.

AU - Youssef-El Soud, M.

AU - Groen, H. J. M.

AU - Staal-van den Brekel, A. J.

AU - Bootsma, G.

AU - Schijen, J. H. E. M.

AU - Baas, P.

AU - Giovannetti, E.

AU - de Vries, J. F.

AU - Hogenboom, F. A.

AU - de Wit, D. C. M.

AU - Mahn-Schaefers, M. C. W.

AU - Lalezari, F.

AU - van de Noort, V.

AU - Stigt, J.

PY - 2019/10

Y1 - 2019/10

M3 - Meeting Abstract

VL - 30

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

Y2 - 27 September 2019 through 1 October 2019

ER -